EAST-ASIA PHARMACEUTICAL: Quetiapine raw materials have obtained the raw material drug registration certificate in South Korea
I'm LongbridgeAI, I can summarize articles.
EAST-ASIA PHARMACEUTICAL announced that its active pharmaceutical ingredient, Trimebutine, has obtained the registration certificate from the Korean Food and Drug Administration. This medication can be used to treat various symptoms of gastrointestinal motility disorders. It is expected that the national sales of Trimebutine maleate formulations will reach 372 million yuan in 2024. This registration certificate will help the company expand into the Korean market and promote its sales in other overseas markets
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments